Related Experiment Video
Updated: May 24, 2025
Humanized Mouse Model to Study Bacterial Infections Targeting the Microvasculature
Published on: April 1, 2014
Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy
Abstract:
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We present a case of meningococcal sepsis in a pegcetacoplan-treated patient with aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Insights
Complement C3 inhibitors like pegcetacoplan may increase Neisseria infection risk. This case highlights meningococcal sepsis in a patient treated with pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Area of Science:
- Immunology
- Hematology
Background:
- Complement C5 inhibitors are known to increase the risk of Neisseria infections.
- Pegcetacoplan, a complement C3 inhibitor, is a new treatment for paroxysmal nocturnal hemoglobinuria (PNH).
- PNH is a condition often managed with complement C5 inhibitors.
Observation:
- A patient with aplastic anemia and PNH was treated with pegcetacoplan.
- The patient developed meningococcal sepsis.
Findings:
- This case demonstrates a potential increased risk of Neisseria infections, specifically meningococcal sepsis, in patients treated with the complement C3 inhibitor pegcetacoplan.
- The patient experienced a severe infection despite treatment with a C3 inhibitor.
Implications:
- Clinicians should be vigilant for Neisseria infections in patients receiving pegcetacoplan, even though it targets a different complement component (C3) than traditional C5 inhibitors.
- This case underscores the critical role of the complement system in immune defense against Neisseria species.
- Further research is warranted to fully understand the infection risks associated with complement C3 inhibition.
